Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
14 February 2022

Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France

MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse